KDNY Stock Overview
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Chinook Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.39 |
| 52 Week High | US$40.51 |
| 52 Week Low | US$18.34 |
| Beta | 0.67 |
| 1 Month Change | 2.98% |
| 3 Month Change | 72.68% |
| 1 Year Change | 95.69% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 173.46% |
Recent News & Updates
Recent updates
Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?
May 28
Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth
Feb 14Chinook Therapeutics: Multiple Shots On Goal For IgAN
Aug 31Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%
Aug 12Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line
Aug 08Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease
Jul 05Shareholder Returns
| KDNY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.3% | 4.7% | 0.7% |
| 1Y | 95.7% | 2.7% | 23.9% |
Return vs Industry: KDNY exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: KDNY exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| KDNY volatility | |
|---|---|
| KDNY Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KDNY's share price has been volatile over the past 3 months.
Volatility Over Time: KDNY's weekly volatility has increased from 10% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 214 | Eric Dobmeier | www.chinooktx.com |
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company’s lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases.
Chinook Therapeutics, Inc. Fundamentals Summary
| KDNY fundamental statistics | |
|---|---|
| Market cap | US$2.90b |
| Earnings (TTM) | -US$245.65m |
| Revenue (TTM) | US$5.85m |
495.8x
P/S Ratio-11.8x
P/E RatioIs KDNY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KDNY income statement (TTM) | |
|---|---|
| Revenue | US$5.85m |
| Cost of Revenue | US$193.72m |
| Gross Profit | -US$187.87m |
| Other Expenses | US$57.79m |
| Earnings | -US$245.65m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.42 |
| Gross Margin | -3,211.95% |
| Net Profit Margin | -4,199.93% |
| Debt/Equity Ratio | 0% |
How did KDNY perform over the long term?
See historical performance and comparison